Abstract:Congress Presidents H.H. Kessler, A.C. Haushofer Scientific Committee A.C. Haushofer, H.H. Kessler, B.I. Santner, R.E. Stauber, E. Stelzl Chair of the EFLM Task Force on European Regulatory Affairs, Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, The Netherlands Within the EU, laboratory or in vitro diagnostic (IVD) tests were regulated by the 1998 Directive 98/79/EC on in vitro diagnostic medical devices (IVDD), which mainly governed pre-market production within the manufacturing sector of CE-IVD marked tests. The majority were self-declared by manufacturers, with EU-wide application, and only approximately 10% required certification by notified bodies, appointed by the national competent authorities in Member States. IVDD did not regulate use of in-house devices (IH-IVD, referred to herein as IH-IVD as this is the term used in EU legislation), which are manufactured and used within the same health institution for medical purposes, in keeping with the EU principle of subsidiarity, and consequent national regulation. With the roll out of EU Regulation 2017/746 on in vitro diagnostic medical devices (IVDR), from 26 May 2022 onwards, the EU market access of medical tests -and not the use- is governed by a vastly expanded and upgraded EU regulatory framework. Notably, in-house devices (IH-IVDs) are exempted from the IVDR, except for compliance with Annex I and Art 5. An overview of the major regulatory changes (among them risk based test classification and clinical evidence generation), the amended transition timelines, the role of notified bodies, EU reference laboratories, expert panels, and the Medical Device Coordination Group (MDCG) will be presented. Laboratory medicine plays an increasingly important part in medical decision-making at diagnosis and follow-up and evolution towards "Personalized" or "Precision" medicine in all disciplines. It is, therefore, not surprising that laboratory medicine has a long standing history of self-regulation and laboratory accreditation. Therefore, accredited labs do have a sufficient fundament for manufacture and use of safe and effective IH-IVDs, and can easily embed the IVDR-requirements into their quality management system. Anno 2024, the EU regulatory framework is still under construction and <5% of the class D tests are IVDR-compliant. While large IVD-companies can cope with the new regulation, this is far more difficult for small and medium IVD-enterprises (SMEs). Because the IVDR-compliance assessment by Notified Bodies is experienced as unpredictable, cumbersome and costly, it keeps SMEs away from sufficient return-on-investment . As a consequence, essential niche and orphan disease tests are in danger of being lost, with negative impact on patient management. On top, the diagnostic sector faces two additional key challenges: (1) the stipulation on equivalence of tests (article 5.5d), which imposes restrictions on the further manufacture and use of IH-IVDs once a commercial equivalent is available and (2) the gray area between CE-marked in vitro diagnostics (CE-IVDs), modified CE-IVDs, Research Use Only (RUO) tests, and IH-IVDs. The results of a questionnaire on current diagnostic practice conducted by European medical societies collaborating in the BioMed Alliance indicate widespread use of IH-IVDs in diagnostic laboratories across Europe and emphasize the need to preserve IH-IVDs for essential innovation and for rapid test development during pandemics. Diagnostic equivalents of the European Reference Networks (ERNs) for rare diseases could help ensure affordable and equal access to specialized diagnostics across the EU. Concerted action by clinical and laboratory disciplines, regulators, industry, and patient organizations is needed to prevent discontinuation of essential low volume tests and to support the efficient and effective implementation of the IVDR in a way that preserves innovation and safeguards the quality, safety, and accessibility of innovative diagnostics. On top, a critical appraisal of the IVDR effectiveness is becoming urgent as there is no evidence so far that this enormous investment in clerical paper work, even obliged for conventional tests that have been used for decades, will improve patient management and outcome. In an era of exploding healthcare costs, time is there for considering IVDR justification and reform. In the last decade, scientific advances have laid a solid foundation for the development of routine molecular 'liquid biopsies'. Cell-free DNA and RNA biomarkers can complement or even surrogate tissue biopsy and have been introduced in clinical laboratory practice, especially in prenatal screening and oncology. Through cell-free DNA detection by real-time PCR techniques and next generation sequencing, a simple non-invasive test becomes a liquid biopsy for 1) an -Abstract Truncated-

Editorial to the revision of the "Guideline of the German Medical Association on quality assurance in medical laboratory examinations – Rili-BAEK"

Laborqualität sichern – molekular- und zytogenetische Ringversuche des BVDH e. V.

Benchmarking medical laboratory performance on a global scale

Quality assessment of glucose measurement with regard to epidemiology and clinical management of diabetes mellitus in Germany

A New Strategy for Evaluating the Quality of Laboratory Results for Big Data Research: Using External Quality Assessment Survey Data (2010–2020)

The European Organisation of External Quality Assurance Providers in Laboratory Medicine (EQALM) Statement: guidelines for publishing about interlaboratory comparison studies (PubILC)

Sharing reference intervals and monitoring patients across laboratories – findings from a likely commutable external quality assurance program

Navigation between EQA and sustainability

Longitudinal analysis of 20 Years of external quality assurance schemes for PCR/NAAT-based bacterial genome detection in diagnostic testing

Time to refresh and integrate the JCTLM database entries for total bilirubin: the way forward

Verifying measurements on Siemens Atellica® instruments using clinically acceptable analytical performance specifications

Navigating Quality Assessment Hurdles in Clinical Laboratory Services: A Comprehensive Review in Resource-Limited Settings

Bilirubin measurements in neonates: uniform neonatal treatment can only be achieved by improved standardization

Compliance to specifications in an external quality assurance program: did new biological variation estimates of the European Federation of Laboratory Medicine (EFLM) affect the quality of laboratory results?

Reference, calibration and referral laboratories – a look at current European provisions and beyond

ISMD2024 Thirteenth International Symposium on Molecular Diagnostics

Design of a bi-directional methodology for automated assessment of compliance to continuous application of clinical guidelines, and its evaluation in the type 2 diabetes domain

Moving average quality control of routine chemistry and hematology parameters - a toolbox for implementation

Assessment of System Accuracy, Intermediate Measurement Precision, and Measurement Repeatability of a Blood Glucose Monitoring System Based on ISO 15197

External quality assurance program for diagnostic complement laboratories: evaluation of the results of the past seven years

Definition, Classification, Diagnosis and Differential Diagnosis of Diabetes Mellitus: Update 2023